Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Polysaccharides vaccine

Indications for Use. Pneumococcal polysaccharide vaccine maybe used for immuni2ation of persons two years of age or older who are at increased risk of pneumococcal disease. [Pg.358]

Pneumococcal vaccine. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children age 2-23 months. It is also recommended for certain children age 24-59 months. Pneumococcal polysaccharide vaccine (PPV) is recommended in addition to PCV for certain high-risk groups. See MMWR. 2000 49(RR-9) 1-35. [Pg.684]

Type B vaccine, the Neisseria meningitidis Type A and C vaccine, the 23-valent pneumococcal polysaccharide vaccine and an acellular typhoid vaccine. [Pg.307]

Serious illness and death in COPD patients can be reduced by about 50% with annual influenza vaccination. The optimal time for vaccination is usually from early October through mid-November. All patients with COPD should also receive a one-time vaccination with the pneumococcal polysaccharide vaccine, even though sufficient data supporting its use in COPD patients are lacking.1,2 Patients over 65 years of age should be revacdnated if it has been more than 5 years since initial vaccination and they were less than 65 years of age at the time. [Pg.238]

PCV 7, 7-valent pneumococcal conjugated vaccine PPV 23, 23-valent pneumococcal polysaccharide vaccine. From Advisory Committee on Immunization Practices,18 Committee on Infectious Diseases,16 and Sickle Cell Disease Care Consortium.27... [Pg.1011]

Three typhoid vaccines are available currently for use in the United States (1) an oral live-attenuated vaccine (Vivotif Berna-TM vaccine, Swiss Serum and Vaccine Institute), (2) a parenteral heat-phenol-inactivated vaccine (Typhoid Vaccine, Wyeth-Ayerst), and (3) a parenteral capsular polysaccharide vaccine (Typhim Vi, Pasteur Merieux). Immunization is recommended only for travelers going to endemic areas such as Latin America, Asia, and Africa household contacts of a chronic carrier and laboratory personnel who frequently work with S. typhi.13... [Pg.1120]

Polysaccharide vaccines are poorly immunogenic in children younger than 2 years of age. [Pg.1239]

The first H. influenzae type b vaccine was an aqueous solution of capsular polysaccharide, polyribosylribitol phosphate. As with all polysaccharide vaccines, it showed poor immuno-genicity in children less than 2 years of age. This vaccine is no longer used. [Pg.1241]

The 23-valent pneumococcal polysaccharide vaccine contains 23 serotypes that are responsible for causing more than 80% of invasive S. pneumoniae infections in adults. The vaccine includes those serotypes that are associated with drug resistance. Use of the vaccine will not prevent the development of antibiotic-resistant S. pneumoniae, but is likely to prevent infection from drug-resistant strains. The 23-valent pneumococcal polysaccharide vaccine has demonstrated good immunogenicity in adults, but an individual will not develop immunity to all 23 serotypes following vaccination.10... [Pg.1245]

The 23-valent pneumococcal polysaccharide vaccine is recommended for use in all adults 65 years of age or older and adults less than 65 years who have medical comorbidities that increase the risk for serious complications from S. pneumoniae infection, such as chronic pulmonary disorders, cardiovascular disease, diabetes mellitus, chronic liver disease, chronic renal failure, functional or anatomic asplenia, and immunosuppressive disorders. Alaskan natives and certain Native American populations are also at increased risk. Children over the age of 2 years may be vaccinated with the 23-valent pneumococcal polysaccharide vaccine if they are at increased risk for invasive S. pneumoniae infections, such as children with sickle cell anemia or those receiving cochlear implants. [Pg.1245]

Revaccination with the 23-valent pneumococcal polysaccharide vaccine is recommended for adults over the age of 65 years if the first dose was administered when they were less than 65 years... [Pg.1245]

V. Verez-Bencomo, V. Femandez-Santana, E. Hardy, M. E. Toledo, M. C. Rodriguez, L. Heynngnezz, A. Rodriguez, A. Baly, L. Herrera, M. Izquierdo, A. Villar, Y. Valdes, et al., A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b, Science, 305 (2004) 522-525. [Pg.359]

Vaccines are recommended for high-risk groups. Live oral attenuated vaccine Ty21a and parenteral polysaccharide vaccine have been shown to confer 42% to 77% efficacy for a duration of 3 to 5 years. [Pg.446]

Pneumococcal vaccine. (Minimum age 6 weeks for pneumococcal conjugate vaccine [PCV 2 yeas for pneumococcal polysaccharide vaccine [PW])... [Pg.571]

Meningococcal polysaccharide vaccine (MPSV4). (Minimum age 2 years)... [Pg.571]

Meningococcal vaccine. (Minimum age 7 7 years for meningococcal conjugate vaccine [MCZ4] 2 years for meningococcal polysaccharide vaccine [MPSV4])... [Pg.573]

Because children younger than 2 years of age do not respond adequately to the pneumococcal polysaccharide vaccine, a heptavalent pneumococcal conjugate vaccine was created that can be administered at 2, 4, and 6 months of age and between 12 and 15 months of age. [Pg.586]

A further type of vaccine included in the subunit category is the capsular polysaccharide vaccines, for example, those against Haemophilus influenzae and meningococcal meningitis. In this case an extract of the polysaccharide outer capsule of the bacterium is used as a vaccine and is sometimes conjugated to protein to... [Pg.425]

NMR can also be used to elucidate the structural features of a repeating unit in a polysaccharide and to investigate the conformation and dynamics of polysaccharides.21 A unique polysaccharide structure results in a characteristic proton NMR spectrum. Therefore, NMR is a powerful tool for identifying polysaccharide structures. This remarkable specificity has led to the development of a routine NMR-based identity assay, recently reported by Abeygunawardana et al. for quality control testing of bacterial polysaccharide to be used in formulating a polyvalent pneumococcal polysaccharide vaccine.22... [Pg.322]

Measles, Mumps, Rubella, Varicella Virus Vaccine, Live [MMRV] (Proquad) Meningococcal Conjugate Vaccine (Menactra) Meningococcal Polysaccharide Vaccine (Menomune A/C/YAV-135) Pneumococcal 7-Valent Conjugate Vaccine (Prevnar)... [Pg.51]

Meningococcal Polysaccharide Vaccine (Menomune A/C/Y/ W-135) Uses Immunize against N. meningitidis Action Active immunization )o ei Adults Feds >2y. 0.5 mL SQ (not IM, intradOTnaUy, IV) may rqieat... [Pg.215]

Pneumococcal vaccine, polyvalent [FDA former] Streptococcus pneumonia capsular polysaccharide vaccine [SY]... [Pg.519]

See other pages where Polysaccharides vaccine is mentioned: [Pg.1011]    [Pg.1042]    [Pg.1060]    [Pg.1245]    [Pg.1245]    [Pg.1245]    [Pg.54]    [Pg.460]    [Pg.569]    [Pg.573]    [Pg.581]    [Pg.584]    [Pg.584]    [Pg.1067]    [Pg.1067]    [Pg.719]    [Pg.296]    [Pg.215]    [Pg.433]    [Pg.519]    [Pg.524]    [Pg.1406]    [Pg.1406]    [Pg.1406]    [Pg.215]   
See also in sourсe #XX -- [ Pg.610 ]



SEARCH



© 2024 chempedia.info